Better cancer biomarker discovery through better study design

European Journal of Clinical Investigation

Volumn 42, Issue 12, 2012, Pages 1350-1359

  Rundle, Andrew ^a   Ahsan, Habibul ^b   Vineis, Paolo ^c,d  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Biomarker discovery; Case control; Epidemiology; High throughput

Indexed keywords

TUMOR MARKER;

BIOINFORMATICS; BLOOD SAMPLING; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL GROWTH; DNA DAMAGE; EPIDEMIOLOGY; FOLLOW UP; FREEZE THAWING; GENE MUTATION; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HUMAN; LUNG CANCER; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CASE-CONTROL STUDIES; HUMANS; LOGISTIC MODELS; NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84869882084     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02727.x     Document Type: Review

References (45)

1. Liotta LA, Ferrari M, Petricoin EF. Written in blood. Nature 2003;425:905.
2. Kiehntopf M, Siegmund R, Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 2007;45:1435-49.
3. Ransohoff DF. Research opportunity at the interface of molecular biology and clinical epidemiology. Gastroenterology 2002;122:1199.
4. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
5. Bhattacharya S, Mariani TJ. Array of hope: expression profiling identifies disease biomarkers and mechanism. Biochem Soc Trans 2009;37:855-62.
6. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-6.
7. Zhu J, Yao X. Use of DNA methylation for cancer detection: promises and challenges. Int J Biochem Cell Biol 2009;41:147-54.
8. Vaissiere T, Cuenin C, Paliwal A, Vineis P, Hoek G, Krzyzanowski M et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics 2009;4:221-30.
9. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
10. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44-52.
11. Baker SG. Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst 2009;101:1116-9.
12. Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials 2006;3:43-56.
13. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
14. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
15. Marshall E. Getting the noise out of gene arrays. Science 2004;306:630-1.
16. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
17. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 2007;96:23-50.
18. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
19. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008;54:414-23.
20. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 2007;177:1753-8.
21. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L et al. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2009;47:713-23.
22. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
23. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003;3:433-9.
24. Drukier AK, Ossetrova N, Schors E, Krasik G, Grigoriev I, Koenig C et al. High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics. J Proteome Res 2006;5:1906-15.
25. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901.
26. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
27. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
28. Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772-9.
29. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47:456-62.
30. Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML et al. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 2008;112:544-51.
31. Ho DW, Yang ZF, Wong BY, Kwong DL, Sham JS, Wei WI et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer 2006;107:99-107.
32. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006;12:1536-44.
33. Rothman K. Modern Epidemiology. Boston: Little, Brown and Company, 1986.
34. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2002;2:4.
35. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005;14:1899-907.
36. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008;31:133-9.
37. Liu XP, Shen J, Li ZF, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006;24:747-53.
38. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
39. Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol 2012;25:1023-32.
40. Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998;19:1949-53.
41. Rundle A, Schwartz S. Issues in the epidemiologic analysis and interpretation of intermediate biomarkers. Cancer Epidemiol Biomarkers Prev 2003;12:491-6.
42. Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997;27:319-65.
43. Reid ME, Santella R, Ambrosone CB. Molecular epidemiology to better predict lung cancer risk. Clin Lung Cancer 2008;9:149-53.
44. Langholz B, Clayton D. Sampling strategies in nested case-control studies. Environ Health Perspect 1994;102(Suppl 8):47-51.
45. Andrieu N, Goldstein AM, Thomas DC, Langholz B. Counter-matching in studies of gene-environment interaction: efficiency and feasibility. Am J Epidemiol 2001;153:265-74.